Search clinical trials for: Fluzoparil

Total 72 results

Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma | HRD+Breast Cancer

China
wang shusen

Recruiting

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Food-Effect and Metabolism Study in Healthy Subjects

Solid Tumor

China
Peking University People's Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer

Germline BRCA-mutated HER2-negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.
307 Hospital of PLA; Peking University Cancer Hospital & Institute

Completed

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Advanced Solid Malignancies

China
Atridia Pty Ltd.

Completed

A Trial of SHR3162 in Healthy Caucasian Volunteers

Healthy Volunteers

Australia
Atridia Pty Ltd.

Completed

A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors

Solid Tumors | Neoplasm

Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients

Small Cell Lung Cancer

China
Liu Zhenhua

Not yet recruiting

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Tongji Hospital
First Affiliated Hospital Xi'an Jiaotong University; Wuhan Union Hospital,... and other collaborators

Recruiting

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Sun Yat-sen University

Not yet recruiting

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

China
Chongqing University Cancer Hospital

Not yet recruiting

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

PARP Inhibitor for Esophageal Squamous Cell Carcinoma
Xiaohua Wu MD

Not yet recruiting

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Relapsed Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

China
Fudan University

Recruiting

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
Guangxi Medical University

Not yet recruiting

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

China
Sun Yat-sen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Sarcoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Ovarian Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Jishuitan Hospital

Recruiting

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma

Soft Tissue Sarcoma

China
Ruijin Hospital

Recruiting

PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)

Sarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

China
Jun Guo

Not yet recruiting

Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma

Melanoma
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Triple Negative Breast Cancer

China
Shandong Cancer Hospital and Institute

Unknown

A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma

Glioblastoma
Hunan Province Tumor Hospital

Recruiting

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma (FLYFLY)

Non-Small Cell Lung Cancer

China
University Hospital, Caen

Completed

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Cancer

France
Fudan University

Not yet recruiting

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Renal Impairment

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Completed

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Ovarian Cancer | Triple Negative Breast Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Ovarian Cancer Recurrent
Tianjin Medical University Second Hospital

Unknown

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Small Cell Lung Cancer Extensive Stage

China
Fujian Cancer Hospital

Not yet recruiting

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Ovarian Cancer

China
GE Healthcare
Karolinska University Hospital

Not yet recruiting

Clinical Data Collection On Advanced CT System

CT Photon Counting
Yongpeng Wang

Recruiting

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Metastatic Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer

Small Cell Lung Cancer

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Treatment of Carrying TP53 Harmful Mutations

Advanced Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
The Third Xiangya Hospital of Central South University

Completed

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

Advanced Solid Tumor

China
Sun Yat-sen University

Not yet recruiting

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Ovarian Cancer | Primary Peritoneal Cancer | High Grade Serous Adenocarcinoma of Ovary | High Grade Endometrioid Ovarian Cancer | Fallopian-tube Cancer

China

Search clinical trials for: Fluzoparil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations